Genome-wide CRISPR screen reveals the synthetic lethality between BCL2L1 inhibition and radiotherapy
Life Science Alliance · 2024
DOI: 10.26508/lsa.202302353 ↗Kurz gefasst
Fachartikel in der Zeitschrift Life Science Alliance, 2024. Verfasst von Ling Yin und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Hauptthemen laut MEDLINE: bcl-X Protein, Breast Neoplasms, Synthetic Lethal Mutations. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Cancer Prevention and Research Institute of Texas, HHS | NIH | National Cancer Institute.
Abstract (Originalsprache)
Radiation therapy (RT) is one of the most commonly used anticancer therapies. However, the landscape of cellular response to irradiation, especially to a single high-dose irradiation, remains largely unknown. In this study, we performed a whole-genome CRISPR loss-of-function screen and revealed temporal inherent and acquired responses to RT. Specifically, we found that loss of the IL1R1 pathway led to cellular resistance to RT. This is in part because of the involvement of radiation-induced IL1R1-dependent transcriptional regulation, which relies on the NF-κB pathway. Moreover, the mitochondrial anti-apoptotic pathway, particularly the BCL2L1 gene, is crucially important for cell survival after radiation. BCL2L1 inhibition combined with RT dramatically impeded tumor growth in several breast cancer cell lines and syngeneic models. Taken together, our results suggest that the combination of an apoptosis inhibitor such as a BCL2L1 inhibitor with RT may represent a promising anticancer strategy for solid cancers including breast cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
- Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
- Morgan Welch Inflammatory Breast Cancer Clinic and Research Program, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
- Human Genetics Center, School of Public Health, The University of Texas Health Science Center at Houston, Houston, TX, USA.
- Center for Precision Health, School of Biomedical Informatics, The University of Texas Health Science Center at Houston, Houston, TX, USA.
- Department of Pediatrics Research, Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
ORCID-Profile: Ling Yin, Zhongming Zhao, Xu Feng, Junjie Chen
Förderung
- NCI NIH HHS
- Cancer Prevention and Research Institute of Texas
- HHS | NIH | National Cancer Institute
Zitieren
APA
Yin, L., Hu, X., Pei, G., Tang, M., Zhou, Y., Zhang, H., Huang, M., Li, S., Zhang, J., Citu, C., Zhao, Z., Debeb, B. G., Feng, X., & Chen, J. (2024). Genome-wide CRISPR screen reveals the synthetic lethality between BCL2L1 inhibition and radiotherapy. Life Science Alliance. https://doi.org/10.26508/lsa.202302353
Vancouver
Yin L, Hu X, Pei G, Tang M, Zhou Y, Zhang H, et al. Genome-wide CRISPR screen reveals the synthetic lethality between BCL2L1 inhibition and radiotherapy. Life Science Alliance. 2024. doi:10.26508/lsa.202302353
BibTeX
@article{Yin2024,
author = {Yin, Ling and Hu, Xiaoding and Pei, Guangsheng and Tang, Mengfan and Zhou, You and Zhang, Huimin and Huang, Min and Li, Siting and Zhang, Jie and Citu, Citu and Zhao, Zhongming and Debeb, Bisrat G and Feng, Xu and Chen, Junjie},
title = {Genome-wide CRISPR screen reveals the synthetic lethality between BCL2L1 inhibition and radiotherapy},
journal = {Life Science Alliance},
year = {2024},
doi = {10.26508/lsa.202302353}
}
EUVIMED